Session » Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

Date: Tuesday, November 12, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2443

A Gender-based Analysis of Disease Activity and Its Relationship with Anxiety, Depression, Fatigue, and Fibromyalgia in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2512

A Qualitative Study of Clinicians’ Perspectives on Barriers to Implementation of Treat to Target in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2503

Achilles Tendon Enthesitis and Disease Burden in Psoriatic Arthritis and Axial Spondyloarthritis: Baseline Results from a Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 2449

Assessing Risk of PsA Progression: Results from a Combined Psoriasis-PsA Center Cohort

9:00AM-11:00AM: Abstract Number: 2463

Body Composition and Fat Distribution in Patients with Psoriasis or Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2440

Bone Mineral Density in Psoriatic Arthritis: Results from a Longitudinal Study

9:00AM-11:00AM: Abstract Number: 2477

Burden of Disease at Treatment Initiation Among Biologic-Naïve Patients with Oligoarticular versus Polyarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

9:00AM-11:00AM: Abstract Number: 2505

Can Biologics “Prevent” the Development of Psoriatic Arthritis in Psoriasis Patients? Data from a Large University Hospital Cohort in Argentina

9:00AM-11:00AM: Abstract Number: 2439

Cardiovascular Impact of Hyperuricemia in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2447

Characteristics of Psoriasis Patients with Subclinical Signs of Musculoskeletal Involvement Detected by Fluorescence Optical Imaging and Confirmed by MRI-assessment

9:00AM-11:00AM: Abstract Number: 2461

Clinical Presentation and Treatment of Oligoarticular Psoriatic Arthritis in Canada: High Frequency of Smaller Joint Involvement

9:00AM-11:00AM: Abstract Number: 2483

Comparison Between Composite Activity Indices to Assess Clinical Response to Biological Therapy in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2494

Comparison of Comorbidity in Spondyloarthritis: Influence on Inflammatory Activity in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2500

Current Smoking Status Increases the Risk of Axial Psoriatic Arthritis: An Explanation to Smoking Paradox

9:00AM-11:00AM: Abstract Number: 2497

Description and Prevalence of Spondyloarthritis in Unselected Patients with Psoriasis, Acute Anterior Uveitis, and Inflammatory Bowel Disease Presenting with Undiagnosed Back Pain

9:00AM-11:00AM: Abstract Number: 2482

Differences and Similarities According to Gender in Patients with Psoriatic Arthritis Initiating Biological Therapy

9:00AM-11:00AM: Abstract Number: 2489

Differences in Clinical Characteristics, Quality of Life, Disability, and Work Productivity in Psoriatic Arthritis Patients by Gender: Findings from a Cross-sectional Survey in the US and Europe

9:00AM-11:00AM: Abstract Number: 2504

Differential Expression of Human Endogenous Retroviruses in Psoriatic Disease

9:00AM-11:00AM: Abstract Number: 2515

Disease Activity Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Psoriatic Artrhitis

9:00AM-11:00AM: Abstract Number: 2469

Diversity of Poly-Functional T Cells in Psoriatic Arthritis and Rheumatoid Arthritis and Its Therapeutic Significance

9:00AM-11:00AM: Abstract Number: 2459

Effect of Obesity and Surgical Weight Loss on Joint Surgery Hospitalizations in Psoriatic Arthritis: Data from National Inpatient Sample

9:00AM-11:00AM: Abstract Number: 2492

Efficacy and Safety of Disease-Modifying Drugs in Psoriatic Arthritis (PsA): A Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 2478

Enthesitis Frequency and Treatment Patterns in Patients with Psoriatic Arthritis in Europe and Japan

9:00AM-11:00AM: Abstract Number: 2445

Enthesitis, Dactylitis, and Axial Disease in Psoriatic Arthritis (PsA): Impact on Patient Quality of Life and Work Productivity

9:00AM-11:00AM: Abstract Number: 2486

Evaluation of Clinical and Functional Parameters by Joint Involvement and Remission in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2466

Evolution of Health-Related Quality of Life in Psoriatic Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2448

Factors Associated with Discordance Between Patient and Rheumatologist Assessment of Disease Activity in Psoriatic Arthritis Considered in Remission

9:00AM-11:00AM: Abstract Number: 2460

Frailty in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis: Data from a National Claims Database

9:00AM-11:00AM: Abstract Number: 2446

Gender Differences in Psoriatic Arthritis – Impact on Tumor Necrosis Factor Inhibitors Persistence and Response

9:00AM-11:00AM: Abstract Number: 2484

Gender Influence on Treatment Effectiveness in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2487

Identification of Circulating MicroRNA Signatures in Patients with Psoriasis and Psoriatic Arthritis to Develop Novel Strategies for Early Diagnosis of a Bone and Joint Involvement

9:00AM-11:00AM: Abstract Number: 2493

IL-6 and TNF-α Influence on Clinical Manifestations, Activity and Comorbidity in Psoriatic Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2455

Impact of Enthesitis on Patient Reported Outcomes and Physician Satisfaction with Treatment: Data from a Multinational Patient and Physician Survey

9:00AM-11:00AM: Abstract Number: 2474

Impact of Multidomain Disease Presentations on Overall Disease Burden Among Patients with Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

9:00AM-11:00AM: Abstract Number: 2473

Implementing the Psoriatic Arthritis Disease Activity Score (PASDAS) in Routine Clinical Practice: (im)possible?

9:00AM-11:00AM: Abstract Number: 2498

Incidence and Predictors of Heart Failure in Patients with Psoriatic Disease – a Cohort Study

9:00AM-11:00AM: Abstract Number: 2457

Increased Prevalence of Systemic Lupus Erythematosus Co-morbidity in Patients with Psoriatic Arthritis: A Population-Based Case-Controlled Study

9:00AM-11:00AM: Abstract Number: 2468

JAK-STAT Signaling System in Pannus Formation of Psoriatic Arthritis: A Therapeutic Target

9:00AM-11:00AM: Abstract Number: 2508

Large Joint and Lower Extremity Involvement Has Higher Impact on Disease Outcomes in Oligoarticular PsA

9:00AM-11:00AM: Abstract Number: 2488

MDA Versus DAPSA: Applicability in a Real World

9:00AM-11:00AM: Abstract Number: 2464

Multidisciplinary Unit of Psoriatic Arthritis: Clinical Results

9:00AM-11:00AM: Abstract Number: 2502

Normalization of Inflammatory Gene Expression and Cellular Markers by Abatacept in the Skin Lesions of Psoriatic Arthritis Patients: A Biopsy Substudy of a Phase III Study

9:00AM-11:00AM: Abstract Number: 2495

Oligoarticular Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2480

Opioid Use Surrounding Diagnosis of Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 2467

Pain and Anxiety Are Independent Factors Associated to Sleep Impairment in Psoriatic Arthritis: A Multicentric Study in 14 Countries

9:00AM-11:00AM: Abstract Number: 2499

Predicting Risk of Developing Psoriatic Arthritis (PsA) in Siblings of Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2491

Predictors of DAPSA28 Remission at 6 Months in Bio-Naive Patients with Psoriatic Arthritis Starting a TNF Inhibitor in Clinical Practice– Results from the EuroSpA Collaboration

9:00AM-11:00AM: Abstract Number: 2458

Predictors of Structural Progression in Psoriatic Arthritis: Clinical versus Systemic Inflammation

9:00AM-11:00AM: Abstract Number: 2475

Prevalence of Disease Domain Presentations Among Patients with Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

9:00AM-11:00AM: Abstract Number: 2454

PROMIS Profile29 Differentiates Active Disease from Treat-to-Target State in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2509

Psoriasis Impact on Patient-Reported Outcomes in Psoriatic Arthritis in a Real-World Setting: Results from the APOPSIS Study

9:00AM-11:00AM: Abstract Number: 2451

Rates of Myocardial Infarction, Stroke, and Revascularization Among Patients with Psoriatic Arthritis Treated with Apremilast, Biologics, DMARDs, and Corticosteroids in the US MarketScan Database

9:00AM-11:00AM: Abstract Number: 2441

Rates of Treated Depression Among Patients with Psoriatic Arthritis Treated with Apremilast, Biologics, DMARDs, and Corticosteroids in the US MarketScan Database

9:00AM-11:00AM: Abstract Number: 2444

Real-world Treatment Patterns Among Patients with Psoriatic Arthritis Treated with Biologic Therapies

9:00AM-11:00AM: Abstract Number: 2485

Red Cell Distribution Width Positively Correlates with Atherosclerotic Cardiovascular Disease Risk Score in Psoriatic Arthritis and Decreases with BDMARD Therapy

9:00AM-11:00AM: Abstract Number: 2471

Regional Difference in Disease Burden Among Patients with Psoriatic Arthritis: A Multi-Center Study

9:00AM-11:00AM: Abstract Number: 2470

Relationship Between Serum Calprotectin Level and Presence of Subclinical Atherosclerosis and Arterial Stiffness in Patient with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2514

Relationships Between Minimal Disease Activity and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 2513

Relationships Between Psoriatic Arthritis Disease Activity Score and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 2465

Reliability and Validity of the Self‐Administered Comorbidity Questionnaire in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2496

Serum Metabolomic Analysis of Psoriatic Arthritis Using Solid Phase Microextraction – Liquid Chromatography – High-Resolution Mass Spectrometry Identifies Putative Disease Activity Markers

9:00AM-11:00AM: Abstract Number: 2476

Side Effects of Methotrexate and TNFi: Differences in Tolerability Among Patients with PsA and RA

9:00AM-11:00AM: Abstract Number: 2453

Static and Longitudinal Construct Validity of PROMIS CAT and Profile29 for Assessing Pain Interference, Physical Function and Fatigue in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2506

The ‘Severity of Nail Psoriasis Score’ (SNAPS) Is Feasible, Reliable and Demonstrates Construct Validity Against the mNAPSI in an Observational Cohort of Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2501

The Association Between Metabolic Syndrome and Radiographic Damage in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2490

The Cutaneous Microbiome of Psoriatic Disease Is Influenced by Disease Susceptibility HLA Alleles but Not Clinical Phenotype

9:00AM-11:00AM: Abstract Number: 2507

The Impact of Psoriasis Severity on Outcomes Among Psoriatic Arthritis Patients Receiving Adalimumab

9:00AM-11:00AM: Abstract Number: 2450

The Paradoxical Effect of Depression on Psoriatic Arthritis Outcomes in a Combined Psoriasis-Psoriatic Arthritis Center

9:00AM-11:00AM: Abstract Number: 2452

The Performance of a Multi-marker Genetic Test to Identify Patients with Psoriatic Arthritis Among Psoriasis Patients

9:00AM-11:00AM: Abstract Number: 2442

The Relationship Between Fatigue and Disease Activity as Determined by Different Indices in Patients with Psoriatic Arthritis (PsA)

9:00AM-11:00AM: Abstract Number: 2472

The Role of Ultrasound for the Assessment of Psoriatic Arthritis Patients with Fibromyalgia – Interim Analysis

9:00AM-11:00AM: Abstract Number: 2479

Unmet Treatment Needs in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2462

Use of Complementary and Alternative Medicine (CAM) in a Psoriatic Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 2481

Uveitis in 320 Patients with Psoriatic Arthritis. Epidemiology, Clinical Features and Biological Treatment: Study from a Single University Center

9:00AM-11:00AM: Abstract Number: 2510

Validation of the Modified Stokes Ankylosing Spondylitis Spinal Score (mSASSS) as a Tool to Assess Axial PsA

9:00AM-11:00AM: Abstract Number: 2456

Validity of Patient-reported Cardiovascular Events in a Large Longitudinal Cohort of Patients with Psoriatic Arthritis and Psoriasis

9:00AM-11:00AM: Abstract Number: 2511

What Influences Patients’ Opinion of Remission and Low Disease Activity in Psoriatic Arthritis? Principal Component Analysis of an International Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].